Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy

Journal of Thoracic Oncology

Volumn 6, Issue 5, 2011, Pages 864-874

  Brevet, Marie ^a   Shimizu, Shigeki ^a   Bott, Matthew J ^a   Shukla, Neerav ^a   Zhou, Qin ^a   Olshen, Adam B ^a   Rusch, Valerie ^a   Ladanyi, Marc ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Combination therapy; Cross activation; mTOR inhibitor; Tyrosine kinase inhibitor

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; DALOTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; TYROSINE KINASE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SEQUENCE; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; MALIGNANT MESOTHELIOMA; MICROARRAY ANALYSIS; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RNA INTERFERENCE; SOMATIC MUTATION; WESTERN BLOTTING;

EID: 79955459524     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318215a07d     Document Type: Article

References (40)

1. Maule MM, Magnani C, Dalmasso P, et al. Modeling mesothelioma risk associated with environmental asbestos exposure. Environ Health Perspect 2007;115:1066-1071. (Pubitemid 47317074)
2. Ho L, Sugarbaker DJ, Skarin AT. Malignant pleural mesothelioma. Cancer Treat Res 2001;245:327-373.
3. Martini N, McCormack PM, Bains MS, et al. Pleural mesothelioma. Ann Thorac Surg 1987;4:113-120. (Pubitemid 17004859)
4. Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet 2004;364:1183-1185. (Pubitemid 39296609)
5. Rusch VW. Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care? J Clin Oncol 2003;21:2629-2630. (Pubitemid 46606302)
6. Borasio P, Berruti A, Bille A, et al. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg 2008;33:307-313.
7. Belyanskaya LL, Marti TM, Hopkins-Donaldson S, et al. Human agonistic TRAIL receptor antibodies mapatumumab and lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer 2007;6:66.
8. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007;2:957-965. (Pubitemid 47511601)
9. Thirkettle I, Harvey P, Hasleton PS, et al. Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas. Histopathology 2000;24:522-528. (Pubitemid 30348777)
10. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;357:468-475. (Pubitemid 32266815)
11. Tolnay E, Kuhnen C, Wiethege T, et al. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol 1998;3:291-296. (Pubitemid 28332909)
12. Dazzi H, Hasleton PS, Thatcher N, et al. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990;81:924-926. (Pubitemid 20197007)
13. Mukohara T, Civiello G, Johnson BE, et al. Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. Oncology 2005;68:500-510. (Pubitemid 41160983)
14. Rascoe PA, Cao X, Daniel JC, et al. Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma. J Thorac Cardiovasc Surg 2005;130:393-400. (Pubitemid 41074170)
15. Altomare DA, You H, Xiao GH, et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005;24:6080-6089. (Pubitemid 43080058)
16. Perrone F, Jocollè G, Pennati M, et al. Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma. Eur J Cancer 2010;46:2837-2848.
17. Menges CW, Chen Y, Mossman BT, et al. A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma. Genes Cancer 2010;1:493-505.
18. Kai K, D'Costa S, Sills RC, et al. Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines. Cancer Lett 2009;278: 49-55.
19. Jacobson BA, De A, Kratzke MG, et al. Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma. Br J Cancer 2009;101:424-431.
20. Whitson BA, Jacobson BA, Frizelle S, et al. Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Ann Thorac Surg 2006;82:996-1001.
21. Kawaguchi K, Murakami H, Taniguchi T, et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 2009;30:1097-1105.
22. Mukohara T, Civiello G, Davis IJ, et al. Inhibition of the met receptor in mesothelioma. Clin Cancer Res 2005;11:8122-8130. (Pubitemid 41698757)
23. Jagadeeswaran R, Ma PC, Seiwert TY, et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006;66:352-361. (Pubitemid 43166042)
24. Govindan R, Kratzke RA, Herndon JE II, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005;11:2300-2304. (Pubitemid 40490190)
25. Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007;25:2406-2413. (Pubitemid 46999211)
26. López-Lago MA, Okada T, Murillo MM, et al. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrindependent mTORC1 signaling. Mol Cell Biol 2009;29:4235-4249.
27. James MF, Han S, Polizzano C, et al. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 2009;29: 4250-4261.
28. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007;26:1932-1940. (Pubitemid 46474636)
29. Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. J Chem Biol 2008;1:27-36.
30. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104: 20932-20937.
31. Reznik TE, Sang Y, Ma Y, et al. Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res 2008;6:139-150. (Pubitemid 351378174)
32. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003; 63:7345-7355. (Pubitemid 37413476)
33. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043. (Pubitemid 46799492)
34. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003;63:6272-6281. (Pubitemid 37255174)
35. Tengs T, Lee JC, Paez JG, et al. A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing. Cancer Lett 2006;239:227-233. (Pubitemid 43974865)
36. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287-290. (Pubitemid 47574858)
37. Huang PH, Mukasa A, Bonavia R, et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 2007;104:12867-12872. (Pubitemid 47255246)
38. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-1508. (Pubitemid 43259931)
39. Tamburini J, Chapuis N, Bardet V, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008;111:379-382.
40. Wang MY, Lu KV, Zhu S, et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 2006;66:7864-7869. (Pubitemid 44299148)